California-based real-world information platform Atropos Well being has secured $33 million in Sequence B funding.
Valtruis led the funding spherical, which included new buyers McKesson Ventures, Merck GHI Fund and Cencora Ventures.
Present buyers Emerson Collective, Breyer Capital and Presidio Ventures additionally participated within the spherical.
Mike Spadafore, managing director of Valtruis, will be part of the corporate’s board of administrators.
WHAT IT DOES
The California-based firm, based in 2019, affords AI improvements, proof era, analytics augmentation and information analysis to assist physicians entry real-world proof to information medical selections and analysis.
The corporate additionally affords a platform dubbed ChatRWD, an LLM-powered chat device for medical analysis that goals to eradicate hallucination threat by using the corporate’s real-world information platform, GENEVA OS.
Atropos will use the funds to increase into oncology and specialty care with the assistance of one among its new buyers Cencora, previously AmerisourceBergen. Cencora is a drug-wholesale firm and contract-research group.
The funds may also help the complete launch of ChatRWD.
“The way forward for value-based care is about making evidence-based selections; persevering with to ship high-quality proof to well being techniques permits them to implement applications and processes that drive distinctive affected person outcomes whereas minding the underside line,” Dr. Brigham Hyde, CEO and cofounder of Atropos Well being, instructed MobiHealthNews in an electronic mail.
“Proof is extra vital than ever, particularly with regards to oncology care. It is evolving consistently, and the stakes are extremely excessive. By investing in our options and sustaining transparency in our methodologies, we empower well being system and life science companions to make selections primarily based on real-world proof for most cancers sufferers and all sufferers, fostering actually customized drugs and reworking the panorama of healthcare.”
MARKET SNAPSHOT
Final yr, Atropos introduced it accomplished a strategic financing spherical, a yr after securing $14 million in a Sequence A funding spherical.
The corporate additionally introduced a partnership with data-sharing expertise platform Datavant, that will permit every firm’s members to entry the opposite firm’s choices.
Earlier this yr, Atropos introduced that healthcare-data analytics firm Arcadia had joined its well being portfolio. This is able to permit Arcadia’s supplier clients and life sciences customers to entry its datasets for value-based care and medical decision-making.
The corporate has additionally partnered with medical analytics and affected person chart summarization firm KAID Well being, healthcare-data firm SEQSTER and Janssen Analysis & Improvement, a Johnson & Johnson firm.
